Skip to content



During clomiphene citrate treatment, dominant follicles luteinized during cycle two; during hMG treatment, no dominant follicle growth was observed during cycle two; during hMG treatment with a higher dose, follicles luteinized during cycles two and three. During IVF-ET, the embryo quality was not high, and the PRL level increased with E2. Follicular dysplasia may be related to mental stress and high PRL levels. Outcome in patients with peripartum cardiomyopathy (PPCM) is variable.

  • The pharmacodynamic actions of cabergoline not correlated with the therapeutic effect only relate to blood pressure decrease.
  • Before administration of cabergoline, pregnancy should be excluded.
  • If fibrotic valvular disease is detected, the patient should not be treated with cabergoline.
  • Erythrocyte sedimentation rate (ESR) has been found to be abnormally increased in association with pleural effusion/fibrosis.

Inhibition of LH secretion causes luteal degradation, luteal dysfunction, a high spontaneous abortion rate, and a high risk of infertility. Depending on your prolactinoma, your symptoms and your situation, you may need no treatment at all, or there may be alternatives such as oestrogen or testosterone treatment. If you are not able to tolerate treatment with cabergoline, or if it is not effective in your case, there are similar medications that can be considered, or other treatment options including pituitary surgery.

Long-term safety of cabergoline in hyperprolactinaemia

However, her cardiac enzymes were mildly elevated with creatinine kinase 317 U/L (24–173) and troponin T 0.18 ug/L (0–0.10). Treatment of hyperprolactinaemic disorders Initially, 500 micrograms per week given in either one dose, or as two doses on separate days e.g. on Mondays and Thursdays. suppresses lactation through its inhibition of prolactin release from the anterior pituitary gland. Therefore, it is not recommended for any woman wishing to breastfeed.

Side Effects

Usually your specialist will recommend a low starting dose to reduce the risk of side-effects, gradually increasing the dose if necessary as your body gets used to the medication. There are no adequate and well-controlled studies from the use of cabergoline in pregnant women. Animal studies have not demonstrated teratogenic effects, but reduced fertility and embryo-toxicity were observed in association with pharmacodynamic activity (see section 5.3). No information is available about the interaction between cabergoline and other ergot alkaloids; therefore, the concomitant use of these medications during long-term treatment with cabergoline is not recommended.

Synthesis of European pharmacopoeial impurities A, B, C, and D of cabergoline†

If you do not want to become pregnant, you should use non-hormonal contraception (e.g. barrier contraception) as soon as you start taking cabergoline, and discuss contraceptive options with your endocrinologist. Also very rarely, cabergoline can cause psychiatric disturbances or abnormally impulsive behaviour, for example a strong desire to gamble or a greatly increased sex drive. It is worth letting your ‘nearest and dearest’ know about this, just in case they notice any changes of this sort. If you are concerned you should consult your GP or your endocrinologist.